RLYB Rallybio Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1739410 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-32.0%
TTM net income YoY289.2%
TTM EPS YoY145.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,580.9%
Net margin6,177.4%
FCF margin—
EBITDA margin-5,579.0%
Returns
ROE34.5%
ROA32.8%
ROIC (approx.)-149.0%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets3.4%
Debt / equity0.00x
Current ratio28.87x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.16x
Accruals ratio-5.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $858,000 | $636,000 |
| R&D expense | $19.60M | $41.51M |
| SG&A expense | $14.32M | $19.62M |
| Operating income | -$33.06M | -$60.50M |
| Pretax income | -$8.98M | -$55.54M |
| Income tax | $0 | $0 |
| Net income | -$8.98M | -$57.77M |
| EBITDA | -$32.97M | -$60.37M |
| EPS (basic) | -1.59 | -10.61 |
| EPS (diluted) | -1.59 | -10.61 |
| Weighted avg. shares (diluted) | 5.63M | 5.44M |
| Balance sheet | ||
| Cash & equivalents | $31.37M | $13.90M |
| Short-term investments | $23.36M | $51.61M |
| Current assets | $61.25M | $67.84M |
| PP&E, net | $23,000 | $115,000 |
| Total assets | $62.26M | $68.11M |
| Current liabilities | $4.22M | $6.24M |
| Total liabilities | $4.30M | $6.45M |
| Shareholders' equity | $57.96M | $61.65M |
| Shares outstanding | 5.28M | 5.19M |
| Cash flow statement | ||
| Operating cash flow | -$29.81M | -$49.28M |
| Capital expenditure | — | $0 |
| Free cash flow | — | -$49.28M |
| Investing cash flow | $47.27M | $33.49M |
| Financing cash flow | $16,000 | $5.20M |
| Depreciation & amortization | $92,000 | $131,000 |
| Stock-based compensation | $5.31M | $7.99M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.